Ovid Therapeutics Bullish Outlook Strengthened By Positive 2-Year Open Label Trial Results
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for Dravet Syndrome and Lennox-Gastaut Syndrome. Find out why OVID stock is a Buy.